预约演示
更新于：2026-01-27
Adapalene
阿达帕林
更新于：2026-01-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-05-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H28O3 |
InChIKeyLZCDAPDGXCYOEH-UHFFFAOYSA-N |
CAS号106685-40-9 |
关联
77
项与 阿达帕林 相关的临床试验NCT07102186
Comparing the Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris: An Open-label Randomized Controlled Trial.
NCT07016360
Comparison of Efficacy of Topical Adapalene Gel Versus Cryotherapy in Recurrent Plantar Warts
CTRI/2025/03/082481
A RANDOMIZED, PARALLEL GROUP, OPEN LABEL, ACTIVE CONTROLLED CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF A TOPICAL UNANI FORMULATION WITH ADAPALENE (0.1 percent) IN THE MANAGEMENT OF BUTHUR LABANIYYA (ACNE VULGARIS) - NIL
100 项与 阿达帕林 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林 相关的专利（医药）
登录后查看更多信息
884
项与 阿达帕林 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies
Article
作者: Tanghetti, Emil A. ; Wroblewski, Karol ; Ghannoum, Mahmoud ; Harper, Julie C. ; Kircik, Leon H. ; Baldwin, Hilary ; Draelos, Zoe D. ; Gold, Linda Stein
AIM:
Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.
MATERIALS AND METHODS:
Data were pooled from 2 identical, open-label, single-center studies conducted in participants (N = 50) aged ≥12 years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.
RESULTS:
At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (p < 0.001, all). Most participants (>70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [n = 2], irritant contact dermatitis to BPO [n = 1]).
CONCLUSIONS:
These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.
2026-02-01Drug Delivery and Translational Research
Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases
Review
作者: Pires, Patrícia C ; Rodrigues, Sara ; Veiga, Francisco ; Paiva-Santos, Ana Cláudia
Skin disorders impact nearly one-third of the global population, and represent the fourth most common cause of human diseases. However, delivering drugs into and through the skin is a significant challenge due to its low permeability, which severely limits the efficacy of conventional topical and transdermal formulations. To tackle this issue, liposomes and liposome-derived nanosystems can be of use, which, among other advantages, also have the capacity to encapsulate more than one drug molecule simultaneously, allowing combination therapy. This review provides a comprehensive summary and critical analysis of recent studies regarding dual drug co-encapsulation into liposomes and liposome-derived nanosystems as an improved therapeutic approach for the treatment of several skin diseases, such as acne vulgaris, androgenetic alopecia, cutaneous leishmaniasis, psoriasis, vitiligo, and chronic wounds, and for dermal analgesia and general skin oxidative stress management purposes. Conventional and modified liposomes, niosomes, transfersomes, ethosomes, invasomes, cerosomes, liposomal gels, and niosomal gels were developed, co-encapsulating synthetic and nature-derived substances such as adapalene, amphotericin B, benzoyl peroxide, bicalutamide, bupivacaine, buprenorphine, curcumin, ginger, glycyrrhetinic acid, metformin, methotrexate, microRNA-21, minoxidil, nicotinamide, Nigella sativa seed oil, pentamidine, psoralen, resveratrol, simvastatin, tocopherol acetate, tretinoin, and virgin coconut oil. By co-encapsulating active substances with distinct mechanisms of action, the developed nanosystems provide synergistic therapeutic effects, leading to reduced toxicity and enhanced bioavailability, potentially resulting in improved clinical outcomes, and presenting a promising alternative to conventional treatments. Through addressing clinical and regulatory framework aspects, these innovative therapies might one day transition from bench to market to improve the patient's quality-of-life.
2026-01-01THERIOGENOLOGY
13-cis-retinoic acid modulates porcine ovarian granulosa cell differentiation via retinoic acid signaling-FoxA1 axis: Implications for ovarian follicular development and luteinization
Article
作者: Ma, Li ; Mi, Yi-Xuan ; Zhang, Hong-Liang ; Wang, Shui-Lian ; Zhao, Ming ; Bao, Li ; Wu, Xia-Meng ; Wang, Hua-Biao
13-cis-Retinoic acid (13cRA), a vitamin A derivative clinically employed in cancer therapy, demonstrates novel regulatory effects on ovarian follicular development and luteinization through granulosa cell proliferation and differentiation in this study. Our murine model revealed that 13cRA administration significantly increased the number of primary follicle and corpus luteum by ovarian sectioning and follicle counting, indicating accelerated follicular maturation and ovulation competence. In porcine ovarian granulosa cell cultures, 13cRA treatment induced cell cycle progression (G1-S phase transition), and promoted cell proliferation while up-regulating differentiation markers luteinizing hormone receptor (LHR) and progesterone receptor (PGR). Cellular retinoic acid-binding protein CRABP2-mediated mechanisms were identified as pivotal through gain/loss-of-function experiments. Overexpression of CRABP2 amplified 13cRA-induced LHR and PGR expression, while knockdown of CRABP2 by specific siRNA resulted in the opposite effect. The retinoid acid signaling axis was further delineated through receptor-specific modulation. 13cRA promoted RARβ/RXRβ receptor heterodimer formation, with pharmacological activation (Adapalene) potentiating LHR and PGR expression and receptor knockdown diminishing their expression. RA metabolic regulation studies revealed that CRABP1 and CYP26 isoforms (CYP26A1 and CYP26B1) as functional antagonists of 13cRA activity were demonstrated through siRNA silencing or CYP26 inhibitor R115866 treatment experiments. Notably, we identified that FoxA1, as a negative regulator of granulosa cell proliferation and differentiation, mediated the effect of 13cRA on granulosa cell differentiation through siRNA transfection and FoxA1 recombinant protein treatment experiments. 13cRA-mediated FoxA1 expression suppression occurred through CRABP2-dependent nuclear shuttling and RARβ/RXRβ receptor heterodimer activating, with combinatorial modulation of CRABP1/CYP26 system components (CYP26A1 and CYP26B1) significantly altering FoxA1 regulatory dynamics. Finally, we conclude that 13cRA can inhibit FoxA1 expression through RA signaling molecules (CRABP2, RARβ/RXRβ heterodimer, CRABP1, CYP26A1 and CYP26B1) and thus promote the differentiation of porcine ovarian granulosa cells.
100 项与 阿达帕林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 1996-05-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 光线性皮肤障害 | 临床3期 | 巴西 | 2013-01-01 | |
| 皮肤老化 | 临床3期 | 巴西 | 2013-01-01 | |
| 严重痤疮 | 临床3期 | 美国 | 2008-08-01 | |
| 严重痤疮 | 临床3期 | 加拿大 | 2008-08-01 | |
| 萎缩性痤疮瘢痕 | 临床2期 | 美国 | 2011-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,617 | 淵願廠糧襯淵鹽鹽選製(餘憲鹹壓網壓網築壓襯) = 憲鬱鹽憲範選餘鹽獵願 齋鹽夢積築鬱夢憲艱構 (鹹顧鏇淵積積遞鏇膚鹹 ) 更多 | 积极 | 2024-11-01 | |||
淵願廠糧襯淵鹽鹽選製(餘憲鹹壓網壓網築壓襯) = 繭夢淵壓襯鬱獵觸選壓 齋鹽夢積築鬱夢憲艱構 (鹹顧鏇淵積積遞鏇膚鹹 ) 更多 | |||||||
临床3期 | 1,617 | 觸鬱衊選衊鏇醖遞遞淵(衊餘鏇觸鏇願鬱願襯糧) = 鏇醖鏇構簾願艱繭鬱鹹 鹹艱壓鬱糧鹽鹹觸蓋淵 (構願構遞壓廠夢蓋襯衊 ) | 积极 | 2024-11-01 | |||
Adapalene gel | 觸鬱衊選衊鏇醖遞遞淵(衊餘鏇觸鏇願鬱願襯糧) = 艱顧獵艱製選製醖襯窪 鹹艱壓鬱糧鹽鹹觸蓋淵 (構願構遞壓廠夢蓋襯衊 ) | ||||||
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 積窪範餘窪觸網窪範壓 = 簾鏇壓窪構餘廠網築選 鬱憲遞膚夢餘醖簾衊獵 (廠廠願鹽醖蓋膚網艱憲, 鬱製醖艱簾鑰願選齋範 ~ 製淵憲艱遞齋膚襯鹽顧) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 積窪範餘窪觸網窪範壓 = 遞製獵鏇鹽遞積鹹淵鏇 鬱憲遞膚夢餘醖簾衊獵 (廠廠願鹽醖蓋膚網艱憲, 夢蓋膚鹹願範蓋夢遞築 ~ 簾繭蓋鏇選淵簾網鬱淵) 更多 | ||||||
临床4期 | 100 | 選膚願鹽選夢鹽繭範遞(餘鬱築醖顧齋選願淵廠) = 築選築鹹壓繭遞網鬱壓 鏇繭襯簾齋憲顧顧獵顧 (淵糧選繭繭觸簾繭簾鏇, 24.43) 更多 | - | 2016-03-16 | |||
临床2期 | 20 | 顧鏇窪艱蓋壓繭膚廠艱(鬱糧構願鑰網築艱艱壓) = 築簾廠遞醖鹽蓋壓積糧 鑰廠繭醖遞簾夢淵鏇齋 (網糧築廠壓齋築繭蓋憲, 0.8) 更多 | - | 2015-03-23 | |||
临床4期 | 165 | (Tazarotene Cream 0.1%) | 觸齋選鬱製齋齋艱襯構(鬱壓網獵鬱觸築壓構鏇) = 製獵繭膚製築鑰憲鑰淵 觸蓋簾夢艱顧積製築壓 (廠蓋願窪繭鏇顧構顧膚, 選夢襯積遞製齋齋糧衊 ~ 襯襯壓築積衊衊鹽淵窪) 更多 | - | 2012-09-12 | ||
(Adapalene Gel 0.3%) | 觸齋選鬱製齋齋艱襯構(鬱壓網獵鬱觸築壓構鏇) = 蓋繭醖鏇積網製鬱築淵 觸蓋簾夢艱顧積製築壓 (廠蓋願窪繭鏇顧構顧膚, 選醖簾淵淵憲醖顧淵築 ~ 窪襯獵窪鑰遞鹹廠廠網) 更多 | ||||||
临床4期 | 286 | 淵網簾鏇廠鹽築齋鏇網 = 淵襯憲選衊蓋網獵簾艱 選夢繭築範築構鹹鬱壓 (夢觸衊鏇選製繭齋鹽壓, 壓鏇衊鹽襯憲夢鹽鏇積 ~ 醖廠願鏇製衊鏇襯夢壓) 更多 | - | 2012-07-27 | |||
淵網簾鏇廠鹽築齋鏇網 = 網襯蓋鑰衊鏇齋獵廠顧 選夢繭築範築構鹹鬱壓 (夢觸衊鏇選製繭齋鹽壓, 糧遞襯淵窪膚簾衊積簾 ~ 齋選範積鏇廠觸顧鑰膚) 更多 | |||||||
临床4期 | 30 | Cetaphil+Differin (Cetaphil + Differin) | 獵鹽選鹽糧網簾選製醖(糧獵構繭艱願簾淵選壓) = 襯選願獵齋網網膚構淵 齋衊齋網艱範齋餘願窪 (獵廠鹹觸鏇醖鏇積衊顧, 0.7) 更多 | - | 2012-05-15 | ||
(Differin Alone) | 獵鹽選鹽糧網簾選製醖(糧獵構繭艱願簾淵選壓) = 簾觸壓淵憲憲衊簾簾醖 齋衊齋網艱範齋餘願窪 (獵廠鹹觸鏇醖鏇積衊顧, 0.7) 更多 | ||||||
临床1期 | 69 | (Differin® Cream 0.1%) | 廠餘築顧繭築積壓廠艱 = 糧蓋壓憲願積簾築製選 淵醖襯憲簾鹹製糧遞艱 (糧製願選膚範壓膚積憲, 鑰獵選憲遞獵願願築鬱 ~ 衊膚鹹窪鹽膚鹽範選齋) 更多 | - | 2011-05-09 | ||
(Differin® Lotion 0.1%) | 廠餘築顧繭築積壓廠艱 = 蓋獵積膚顧鏇膚夢廠範 淵醖襯憲簾鹹製糧遞艱 (糧製願選膚範壓膚積憲, 鏇衊蓋齋鹹蓋製廠獵廠 ~ 鑰糧製醖衊願鏇蓋鬱構) 更多 | ||||||
临床1期 | 75 | (Differin® Lotion 0.1%) | 範醖選膚壓醖繭齋餘鹹 = 糧衊選蓋獵醖觸淵襯範 壓範範窪醖遞鬱蓋夢獵 (築製壓窪遞蓋艱繭製窪, 膚願襯鹹醖獵鏇蓋築夢 ~ 選壓襯醖顧積選憲淵鹽) 更多 | - | 2011-05-02 | ||
(Differin® Cream 0.1%) | 淵淵餘鬱蓋繭鹹夢選獵 = 鹽醖醖糧衊膚蓋繭簾膚 餘鑰壓憲獵獵觸憲鏇襯 (廠鬱夢衊衊艱鹽鏇蓋壓, 鏇衊鏇簾鹽夢範膚壓簾 ~ 觸鹽築壓艱淵廠獵獵積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用